CP-25 monotherapy and combined administration ameliorate progression of animal arthritis model by in

• 作 者: YANG Xue-zhi ZHAO Ying-jie SU
• 机 构: InstituteofClinicalPharmacology
• 出 处: 中国药理学与毒理学杂志
• 发表日期: 2019年9期
• 关键词: CP-25 drug combination GRK2 P-ERK EP4
• 基金项目: National Natural Science Foundation of China(81330081,81673444,31200675,81573443),Anhui Province Natural Science Fund(outstanding youth)(170808J10),Key Projects of Outstanding young Talent Support Pro

OBJECTIVE Increased efficacy without increased toxicity is expected when treating rheumatoid arthritis(RA).However,there are many difficulties associated with currently available RA treatments.Reportedly,CP-25,a new compound developed by our group,signifi